Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-625-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

New RDM0041H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Serum, Whole blood, Tissue

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 6.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 7.2%

Spiking Recovery


Dilution Linearity



Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-625-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology, Pulmonary diseases


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-625 has been found in various tumors, such as gastric cancer, pancreatic cancer, glioma and melanoma. miR-625 has been shown to be down regulated in gastric cancer. miR-625 is responsible for the regulation of metastasis in gastric tumor cells, and therefore downregulation of miR-625 in increased metastasis. Glioma tissues overexpressing HIF1α exhibited a low expression of miR-625-5p. The knockdown of RHPN1-AS1 inhibited the proliferation, migration and invasion activity of glioma cells via regulating miR-625-5p/REG3A expression. miR-625-5p regulated PKM2 expression on mRNA and protein level in melanoma cells (MC). There was a negative relationship between miR-625-5p and PKM2 expression in the clinical melanoma samples so miR-625-5p/PKM2 plays a role in MC glucose metabolism.

miR-625-5p inhibited cardiac hypertrophy through targeting STAT3 and CaMKII, suggesting miR-625-5p as a novel negative regulator of cardiac hypertrophy. Expression levels of miR-421, miR-1233-3p and miR-625-5p are lower in TOF patients with symptomatic right heart failure and thus may indicate disease progression in these patients. Aortic valve stenosis (AS) is a major cause of morbidity and mortality, with no effective medical therapies. In this connection, downregulation of miR-122-5p, miR-625-5p, miR-30e-5p and upregulation of miR-21-5p and miR-221-3p was confirmed. The identification of a group of tissue miRNA associated with AS may contribute to the development of new therapeutic approaches to AS.

miR 625-5p may function as an inhibitor of asthma airway inflammation in human bronchial epithelial cells (HBECs) by targeting AKT2. Three miRNAs (miR-22-3p, miR 513a-5p, miR-625-5p) were significantly downregulated in the asthma group compared with the control group.

Summary References (9)

References to miR-625-5p

  • Wang M ea al.: Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Letters. 2012; 586 (16): 2382–8.
  • Su H, Zou D, Sun Y, Dai Y: Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p. Cell Mol Biol Lett. 2019; 24: 24.
  • Cui P, Su J, Li Q, Xu G, Zhu N: LncRNA RHPN1-AS1 Targeting miR-625/REG3A Promotes Cell Proliferation And Invasion Of Glioma Cells. Onco Targets Ther. 2019;12: 7911-7921.
  • Zhang H et al.: miR-625-5p/PKM2 negatively regulates melanoma glycolysis state. J Cell Biochem. 2019; 120(3): 2964-2972.
  • Cai K, Chen H: MiR-625-5p inhibits cardiac hypertrophy through targeting STAT3 and CaMKII. Hum Gene Ther Clin Dev. 2019; 30(4): 182-191.
  • Abu-Halima M, Meese E, Keller A, Abdul-Khaliq H, Rädle-Hurst T: Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure. J Transl Med. 2017; 15(1): 156.
  • Coffey S, Williams MJ, Phillips LV, Galvin IF, Bunton RW, Jones GT: Integrated microRNA and messenger RNA analysis in aortic stenosis. Sci Rep. 2016; 6: 36904.
  • Qian FH1, Deng X1, Zhuang QX1, Wei B1, Zheng DD: miR‑625‑5p suppresses inflammatory responses by targeting AKT2 in human bronchial epithelial cells. Mol Med Rep. 2019; 19(3): 1951-1957.
  • Dong X, Xu M, Ren Z, Gu J, Lu M, Lu Q, Zhong N: Regulation of CBL and ESR1 expression by microRNA-22‑3p, 513a-5p and 625-5p may impact the pathogenesis of dust mite-induced pediatric asthma. Int J Mol Med. 2016; 38(2): 446-56.
Related Products Docs